LIANHE TECHNOLOGY(SZ:002250)2025-12-21 08:52Group 1: Agricultural Protection Business - The agricultural protection business currently accounts for a significant portion of the company's revenue, with plans for future development focusing on maintaining steady growth in this concentrated industry [1] - The company has established long-term strategic partnerships with multiple international agricultural companies, covering all stages of the product lifecycle [1] - The company has production bases across China and an overseas base in the UK, with plans to establish Malaysia as a second overseas base to enhance supply chain differentiation [1] Group 2: Pharmaceutical Business Development - The pharmaceutical business is rapidly developing, with a focus on attracting new strategic and high-viscosity clients [2] - The company has formed stable commercial relationships with several high-quality domestic and international clients, expanding its business cooperation scope [2] - Future growth in the pharmaceutical sector is expected as the company continues to promote products under patent protection and enhance its technical capabilities [2] Group 3: Research and Development Directions - The company is expanding its R&D efforts from traditional small molecule drugs to include amino acids, peptides, and other advanced drug delivery systems [3] - The team is focused on accelerating the transition of early clinical projects for clients, providing diverse linker synthesis services for ADC/PROTAC drugs [3] - These new directions are anticipated to broaden the company's CDMO service offerings and enable the acquisition of more projects [3] Group 4: CDMO Capabilities and Client Relationships - The company emphasizes enhancing its technical innovation, safety standards, production management, and quality assurance systems to meet client needs [4] - A strong intellectual property confidentiality system and a commitment to integrity have earned the company recognition from leading global agricultural and pharmaceutical clients [4] - The selection of suppliers by international clients is based on comprehensive evaluations of technology, regulations, environmental standards, and quality, leading to stable and long-term partnerships [5] Group 5: Capital Operations and Financial Outlook - Currently, the company has no plans for capital operations focused on secondary market financing, with recent capital expenditures directed towards the construction of coastal and Malaysian bases [5] - The net cash flow from operating activities for the first three quarters of 2025 was approximately 9 billion, sufficient to support planned capital expenditures [5] - Future financing plans will be evaluated based on strategic investment needs and market conditions [5] Group 6: New Energy Business - The company primarily focuses on the sales of lithium hexafluorophosphate and electrolyte products, with ongoing technical improvements in the lithium hexafluorophosphate project [5] - Revenue from the new energy business is expected to break through in 2025, with plans to deepen market penetration and optimize the supply chain [5]